Abstract
A variety of antigens have been identified on the surface of the malignant cell. However, identical antigens are often found on non-malignant cells of the same or different histological origin, or of a different stage of embryonic development1–5. Many of these tumour-associated antigens appear to be only incidentally expressed on neoplastic cells. Clearly, it would be of great interest to identify cell-surface antigens whose expression is associated specifically with the transformed state and linked directly with the mechanisms responsible for transformation. The detection of activated cellular oncogenes in human and animal cancer cells by the technique of DNA transfection has allowed the isolation of genetic elements which are thought to have a critical role in malignancy6,7. Here, in an effort to identify cell-surface antigens associated with the neoplastic process, we have generated hybridomas which secrete monoclonal antibodies that react specifically with cell-surface determinants found on NIH 3T3 cells transformed by transfection with a group of rat neuroblastoma oncogenes. These antibodies bind to and immunoprecipitate a phosphoprotein of relative molecular mass 185,000 (185 K) from a DNA donor rat neuroblastoma and 13 independent rat neuroblastoma DNA transfectants. There was no antibody reactivity with normal NIH 3T3 cells or with NIH 3T3 cells transformed by various other agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Old, L. J. Cancer Res. 41, 361–375 (1981).
Bortin, M. M. & Truitt, R. L. Transplantn Proc. 12, 1–218 (1980).
Carroll, A. M., Zalutsky, M. R., Benecerraf, B. & Greene, M. I. Survey and Synthesis of Pathology Research Vol. 3, 189–200 (1984).
Hadas, E., Hurwitz, E. & Eshhar, Z. Int. J. Cancer 33, 369–374 (1984).
Embleton, M. J. & Heidelberger, C. Cancer Res. 35, 2049–2055 (1975).
Land, H., Parada, L. F. & Weinberg, R. A. Science 222, 771–778 (1983).
Cooper, G. M. Science 217, 801–806 (1982).
Shih, C., Padhy, J. C., Murray, M. & Weinberg, R. A. Nature 290, 261–264 (1981).
Padhy, L. C., Shih, C., Cowing, D., Finkelstein, R. & Weinberg, R. A. Cell 28, 865–871 (1982).
Schechter, A. et al. Nature 312, 513–516 (1984).
Lindmo, T., Davies, C., Rofstad, E. K., Fodstad, O. & Sundan, A. Int. J. Cancer 33, 167–171 (1984).
Rohrschneider, L. R. Proc. natn. Acad. Sci. U.S.A. 77, 3514–3518 (1980).
Der, C. J. & Cooper, G. M. Cell 32, 201–208 (1983).
Becker, D., Lane, M. A. & Cooper, G. M. Proc. natn. Acad. Sci. U.S.A. 79, 3315–3319 (1982).
Goubin, G., Goldman, D. S., Luce, J., Neiman, P. E. & Cooper, G. M. Nature 302, 114–119 (1983).
Hampe, A., Gabet, M., Sherr, C. J. & Galibert, F. Proc. natn. Acad. Sci. U.S.A. 81, 85–89 (1984).
Hayman, M. J. et al. Cell 32, 579–588 (1983).
Bishop, J. M. A. Rev. Biochem. 52, 301–354 (1983).
Das, M. et al. Proc. natn. Acad. Sci. U.S.A. 74, 2790–2794 (1977).
Glenn, K., Bowen-Pope, D. F. & Ross, R. J. biol. Chem. 257, 5172–5176 (1982).
Downward, J. et al. Nature 307, 521–527 (1984).
Sefton, B. M., Beemon, K. & Hunter, T. J. Virology 28, 957–971 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drebin, J., Stern, D., Link, V. et al. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312, 545–548 (1984). https://doi.org/10.1038/312545a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/312545a0
This article is cited by
-
PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
BMC Cancer (2022)
-
Current status and future perspectives in HER2 positive advanced gastric cancer
Clinical and Translational Oncology (2022)
-
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Gastric Cancer (2021)
-
An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice
Cancer Immunology, Immunotherapy (2019)
-
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14
Oncogene (2013)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.